Results 1 to 10 of about 3,471,294 (187)

Evolution of β-lactamase-mediated cefiderocol resistance. [PDF]

J Antimicrob Chemother, 2022
Cefiderocol is a novel siderophore β-lactam with improved hydrolytic stability toward β-lactamases, including carbapenemases, achieved by combining structural moieties of two clinically efficient cephalosporins, ceftazidime and cefepime.
Fröhlich C, Sørum V, Tokuriki N, Johnsen PJ, Samuelsen Ø.   +4 more
europepmc   +9 more sources

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance [PDF]

Antibiotics, 2022
Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms (including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon according to large multinational cohorts, including against isolates resistant to ...
Stamatis Karakonstantis, Maria Rousaki, Evangelos I. Kritsotakis   +2 more
doaj   +7 more sources

Cefiderocol Resistance in Klebsiella pneumoniae Is Linked to SHV Extended-Spectrum β-Lactamase Activities and Functional Loss of the Outer Membrane Porin OmpK35 [PDF]

Microbiology Spectrum, 2023
Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj   +5 more sources

Cefiderocol Resistance in Pseudomonas aeruginosa ST175: A Case Report with Genomic Analysis [PDF]

Antibiotics
Background: Cefiderocol, a novel siderophore cephalosporin, has shown promising activity against multidrug-resistant (MDR) Gram-negative pathogens, including metallo-β-lactamase (MBL) producers.
Rosario Fernández Fernández, Alberto Badillo Carrasco, Natalia Chueca Porcuna, Antonio Martínez Cabezas, Manuel Colmenero Ruiz   +4 more
doaj   +5 more sources

Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China [PDF]

Microbiology Spectrum, 2022
Cefiderocol is a novel siderophore cephalosporin exhibiting potent antimicrobial activities. Although cefiderocol has not been approved in China, resistance is emerging.
Peng Lan, Ye Lu, Zhongju Chen, Xueqing Wu, Xiaoting Hua, Yan Jiang, Jiancang Zhou, Yunsong Yu   +7 more
doaj   +5 more sources

Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network [PDF]

Microbiology Spectrum, 2022
Cefiderocol has been approved in the United States and Europe but not in China. We aim to evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to provide baseline data and investigate the resistance mechanism.
Qi Wang, Longyang Jin, Shijun Sun, Yuyao Yin, Ruobing Wang, Fengning Chen, Xiaojuan Wang, Yawei Zhang, Jun Hou, Yumei Zhang, Zhijie Zhang, Liuchun Luo, Zhusheng Guo, Zhenpeng Li, Xin Lin, Lei Bi, Hui Wang   +16 more
doaj   +5 more sources

Mutation in the two-component regulator BaeSR mediates cefiderocol resistance and enhances virulence in Acinetobacter baumannii [PDF]

mSystems, 2023
Acinetobacter baumannii has become one of the most challenging pathogens in many countries with limited treatment options available. Cefiderocol, a novel siderophore-conjugated cephalosporin, shows potent in vitro activity against A. baumannii, including
Xiaochen Liu, Yunjie Chang, Qingye Xu, Wang Zhang, Zhen Huang, Linyue Zhang, Shanshan Weng, Sebastian Leptihn, Yan Jiang, Yunsong Yu, Xiaoting Hua   +10 more
doaj   +4 more sources

Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019-21. [PDF]

JAC Antimicrob Resist
Background Cefiderocol, a novel siderophore cephalosporin, is a promising therapeutic option for infections caused by multidrug-resistant Pseudomonas aeruginosa. We evaluated the activity of cefiderocol against carbapenem-resistant P.
Kocer K, Boutin S, Moll M, Nurjadi D.
europepmc   +5 more sources

The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae. [PDF]

Antimicrob Agents Chemother, 2023
In this study, we aimed to clarify the evolutionary trajectory of a Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) population during β-lactam antibiotic therapy.
Zhang P, Hu H, Shi Q, Sun L, Wu X, Hua X, McNally A, Jiang Y, Yu Y, Du X.   +9 more
europepmc   +3 more sources

Novel PiuC, PirA, and PiuA mutations leading to in vivo cefiderocol resistance progression in IMP-16- and KPC-2-producing Pseudomonas aeruginosa from a leukemic patient [PDF]

Microbiology Spectrum
Pseudomonas aeruginosa is an opportunistic pathogen capable of causing severe infections in immunocompromised individuals, who often require prolonged antibiotic therapy. The emergence of carbapenemase-producing P.
Joaquim Viñes, Sabina Herrera, Andrea Vergara, Ignasi Roca, Jordi Vila, Tommaso Francesco Aiello, José Antonio Martínez, Ana del Río, Carlos Lopera, Carolina Garcia-Vidal, Climent Casals-Pascual, Àlex Soriano, Cristina Pitart   +12 more
doaj   +3 more sources